Specific programme: U.S. National Institutes of Health and the Canadian Institutes of Health Research
UPV/EHU Partner Status:  Consortium Partner
UPV/EHU Supervisor: Jose Luis Nieva Escandon
Project start: 01/10/2011
Project end:   28/02/2018
 

Brief description:  The goal is to produce a vaccine lead for all types of HIV-1 infection, and as such, it is of relevance to all of the key populations targeted by CIHR¿s HIV/AIDS Research Initiative. The investigators seek to produce a vaccine that will mimic the structure of the membrane proximal external region of gp41 (MPER) as it exists on the virus; by mimicking the neutralization-competent structure of the MPER, with the expectation of producing a vaccine that elicits antibodies that will bind to the MPER on the virus and block it from successfully infecting cells.